Annual Accounts Receivable
$457.44 M
+$56.83 M+14.18%
31 December 2023
Summary:
IDEXX Laboratories annual accounts receivable is currently $457.44 million, with the most recent change of +$56.83 million (+14.18%) on 31 December 2023. During the last 3 years, it has risen by +$126.02 million (+38.02%). IDXX annual accounts receivable is now at all-time high.IDXX Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Receivable
$511.25 M
-$22.36 M-4.19%
30 September 2024
Summary:
IDEXX Laboratories quarterly accounts receivable is currently $511.25 million, with the most recent change of -$22.36 million (-4.19%) on 30 September 2024. Over the past year, it has increased by +$58.55 million (+12.93%). IDXX quarterly accounts receivable is now -4.19% below its all-time high of $533.61 million, reached on 30 June 2024.IDXX Quarterly Accounts Receivable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IDXX Accounts Receivable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +14.2% | +12.9% |
| 3 y3 years | +38.0% | +35.7% |
| 5 y5 years | +83.8% | +90.5% |
IDXX Accounts Receivable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +38.0% | -4.2% | +38.8% |
| 5 y | 5 years | at high | +83.8% | -4.2% | +90.5% |
| alltime | all time | at high | +901.2% | -4.2% | +1019.0% |
IDEXX Laboratories Accounts Receivable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $511.25 M(-4.2%) |
| June 2024 | - | $533.61 M(+5.2%) |
| Mar 2024 | - | $507.21 M(+10.9%) |
| Dec 2023 | $457.44 M(+14.2%) | $457.44 M(+1.0%) |
| Sept 2023 | - | $452.70 M(-2.0%) |
| June 2023 | - | $461.86 M(+3.5%) |
| Mar 2023 | - | $446.02 M(+11.3%) |
| Dec 2022 | $400.62 M(+8.8%) | $400.62 M(+3.2%) |
| Sept 2022 | - | $388.07 M(-6.0%) |
| June 2022 | - | $412.90 M(+2.7%) |
| Mar 2022 | - | $402.24 M(+9.2%) |
| Dec 2021 | $368.35 M(+11.1%) | $368.35 M(-2.2%) |
| Sept 2021 | - | $376.76 M(-1.5%) |
| June 2021 | - | $382.31 M(+0.1%) |
| Mar 2021 | - | $381.79 M(+15.2%) |
| Dec 2020 | $331.43 M(+23.1%) | $331.43 M(-1.8%) |
| Sept 2020 | - | $337.59 M(+5.4%) |
| June 2020 | - | $320.32 M(+6.8%) |
| Mar 2020 | - | $299.98 M(+11.4%) |
| Dec 2019 | $269.31 M(+8.2%) | $269.31 M(+0.4%) |
| Sept 2019 | - | $268.32 M(-6.2%) |
| June 2019 | - | $286.15 M(+1.8%) |
| Mar 2019 | - | $281.16 M(+13.0%) |
| Dec 2018 | $248.85 M(+6.1%) | $248.85 M(-5.9%) |
| Sept 2018 | - | $264.56 M(-0.2%) |
| June 2018 | - | $265.01 M(+2.0%) |
| Mar 2018 | - | $259.87 M(+10.8%) |
| Dec 2017 | $234.60 M(+14.7%) | $234.60 M(+2.8%) |
| Sept 2017 | - | $228.16 M(-5.0%) |
| June 2017 | - | $240.26 M(+6.6%) |
| Mar 2017 | - | $225.35 M(+10.2%) |
| Dec 2016 | $204.49 M(+8.6%) | $204.49 M(-0.1%) |
| Sept 2016 | - | $204.70 M(-3.5%) |
| June 2016 | - | $212.23 M(+0.1%) |
| Mar 2016 | - | $212.07 M(+12.6%) |
| Dec 2015 | $188.32 M(+23.6%) | $188.32 M(-1.4%) |
| Sept 2015 | - | $190.90 M(-4.3%) |
| June 2015 | - | $199.44 M(+1.6%) |
| Mar 2015 | - | $196.23 M(+28.8%) |
| Dec 2014 | $152.38 M(-3.6%) | $152.38 M(-5.0%) |
| Sept 2014 | - | $160.47 M(-4.8%) |
| June 2014 | - | $168.64 M(-6.3%) |
| Mar 2014 | - | $179.92 M(+13.8%) |
| Dec 2013 | $158.04 M(+14.3%) | $158.04 M(+4.3%) |
| Sept 2013 | - | $151.57 M(-4.7%) |
| June 2013 | - | $159.12 M(+0.1%) |
| Mar 2013 | - | $158.99 M(+14.9%) |
| Dec 2012 | $138.32 M | $138.32 M(-2.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2012 | - | $141.37 M(-3.9%) |
| June 2012 | - | $147.16 M(-8.6%) |
| Mar 2012 | - | $160.98 M(+13.9%) |
| Dec 2011 | $141.28 M(+17.7%) | $141.28 M(+4.7%) |
| Sept 2011 | - | $134.92 M(-9.6%) |
| June 2011 | - | $149.31 M(+8.6%) |
| Mar 2011 | - | $137.55 M(+14.5%) |
| Dec 2010 | $120.08 M(+4.3%) | $120.08 M(-0.3%) |
| Sept 2010 | - | $120.45 M(-5.3%) |
| June 2010 | - | $127.14 M(-2.6%) |
| Mar 2010 | - | $130.52 M(+13.4%) |
| Dec 2009 | $115.11 M(+3.2%) | $115.11 M(-0.0%) |
| Sept 2009 | - | $115.14 M(-3.1%) |
| June 2009 | - | $118.78 M(+3.1%) |
| Mar 2009 | - | $115.25 M(+3.4%) |
| Dec 2008 | $111.50 M(+2.9%) | $111.50 M(-0.5%) |
| Sept 2008 | - | $112.05 M(-7.1%) |
| June 2008 | - | $120.56 M(-3.7%) |
| Mar 2008 | - | $125.25 M(+15.6%) |
| Dec 2007 | $108.38 M(+33.2%) | $108.38 M(+4.8%) |
| Sept 2007 | - | $103.41 M(-3.1%) |
| June 2007 | - | $106.68 M(+1.8%) |
| Mar 2007 | - | $104.79 M(+28.8%) |
| Dec 2006 | $81.39 M(+13.5%) | $81.39 M(+2.6%) |
| Sept 2006 | - | $79.30 M(-6.1%) |
| June 2006 | - | $84.47 M(+3.1%) |
| Mar 2006 | - | $81.92 M(+14.3%) |
| Dec 2005 | $71.69 M(+9.2%) | $71.69 M(+5.3%) |
| Sept 2005 | - | $68.10 M(-6.9%) |
| June 2005 | - | $73.14 M(-3.3%) |
| Mar 2005 | - | $75.62 M(+15.2%) |
| Dec 2004 | $65.64 M(+21.6%) | $65.64 M(+13.3%) |
| Sept 2004 | - | $57.95 M(-2.3%) |
| June 2004 | - | $59.29 M(-3.5%) |
| Mar 2004 | - | $61.47 M(+13.9%) |
| Dec 2003 | $53.98 M(+18.1%) | $53.98 M(+6.5%) |
| Sept 2003 | - | $50.67 M(-0.2%) |
| June 2003 | - | $50.78 M(-1.5%) |
| Mar 2003 | - | $51.58 M(+12.9%) |
| Dec 2002 | $45.69 M(-10.0%) | $45.69 M(-4.0%) |
| Sept 2002 | - | $47.61 M(-0.8%) |
| June 2002 | - | $48.00 M(-7.1%) |
| Mar 2002 | - | $51.68 M(+1.8%) |
| Dec 2001 | $50.77 M(-11.3%) | $50.77 M(-6.0%) |
| Sept 2001 | - | $53.99 M(-4.4%) |
| June 2001 | - | $56.48 M(-0.6%) |
| Mar 2001 | - | $56.84 M(-0.7%) |
| Dec 2000 | $57.27 M | $57.27 M |
FAQ
- What is IDEXX Laboratories annual accounts receivable?
- What is the all time high annual accounts receivable for IDEXX Laboratories?
- What is IDEXX Laboratories annual accounts receivable year-on-year change?
- What is IDEXX Laboratories quarterly accounts receivable?
- What is the all time high quarterly accounts receivable for IDEXX Laboratories?
- What is IDEXX Laboratories quarterly accounts receivable year-on-year change?
What is IDEXX Laboratories annual accounts receivable?
The current annual accounts receivable of IDXX is $457.44 M
What is the all time high annual accounts receivable for IDEXX Laboratories?
IDEXX Laboratories all-time high annual accounts receivable is $457.44 M
What is IDEXX Laboratories annual accounts receivable year-on-year change?
Over the past year, IDXX annual accounts receivable has changed by +$56.83 M (+14.18%)
What is IDEXX Laboratories quarterly accounts receivable?
The current quarterly accounts receivable of IDXX is $511.25 M
What is the all time high quarterly accounts receivable for IDEXX Laboratories?
IDEXX Laboratories all-time high quarterly accounts receivable is $533.61 M
What is IDEXX Laboratories quarterly accounts receivable year-on-year change?
Over the past year, IDXX quarterly accounts receivable has changed by +$58.55 M (+12.93%)